NDA 017243 · Curium
Ultra-Technekow V4
Technetium Tc-99m Sodium Pertechnetate Generator · Intravenous · Radioactive Diagnostic Agent
Last checked: Nov 19, 2026Latest source record: Jan 30, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1973
Nov 23, 1973
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
2 Phase 3, 0 recruiting
FAERS reports
628
84 serious, 11 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 16, 2024.
INDICATIONS AND USAGE The Ultra-Technekow™ V4 generator is a source of sodium pertechnetate Tc 99m for use in the preparation of FDA-approved diagnostic radiopharmaceuticals, as described in the labeling of these diagnostic radiopharmaceutical kits. Sodium Pertechnetate Tc 99m is used IN ADULTS as an agent for: Thyroid Imaging Salivary Gland Imaging Urinary Bladder Imaging (direct isotopic cystography) for detection of vesico-ureteral reflux Nasolacrimal Drainage System Imaging (dacryoscintigraphy) Sodium Pertechnetate Tc 99m is used IN PEDIATRIC PATIENTS as an agent for: Thyroid Imaging Urinary Bladder Imaging (direct isotopic cystography) for the detection of vesico-ureteral reflux
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 23, 1973 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
- ULTRA-TECHNEKOW V4 · TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR 1-19 CI/GENERATOR · SOLUTION, INTRAVENOUS · Prescription
- ULTRA-TECHNEKOW V4 · TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR 0.25-3 CI/GENERATOR · SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Pertechnetate Generator" as an intervention, any sponsor and status, largest first.
- VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial CancerActive, not recruiting
Mayo ClinicAcademic, hospital or other
NCT03120624 · 34 participants · Start Sep 15, 2017 · Primary completion Aug 29, 2023
Drug: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter; Ruxolitinib Phosphate and 1 more · For: Metastatic Endometrial Carcinoma; Recurrent Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma and 7 more
Sites: Rochester, Minnesota
AHS Cancer Control AlbertaAcademic, hospital or other
NCT01437254 · 30 participants · Start Oct 2011 · Primary completion Apr 2012
Drug: CPERT; GPERT · For: Thyroid Neoplasms
Sites: Edmonton, Canada
- A Study to Compare the Safety and Imaging Pattern of Cyclotron-produced Technetium (CTC) vs. Generator-produced Technetium (G-PERT) in People With Thyroid Disorders Who Need SurgeryPivotal-lookingCompleted
University of AlbertaAcademic, hospital or other
NCT02980679 · 25 participants · Start Mar 3, 2017 · Primary completion Feb 25, 2019
Drug: CTC; G-PERT · For: Thyroid Gland Diseases
Sites: Edmonton, Canada
- Sodium Pertechnetate (99Tc) Injection Generator: 99mTc From Neutron-activation 99Mo v 99mTc From Fission 99MoPivotal-lookingTerminated
University of ManitobaAcademic, hospital or other
NCT03002454 · 4 participants · Start Aug 2016 · Primary completion Nov 2016
Drug: 99mTc MDP Injection:neutron-bombardment · For: Cancer of Bone
Sites: Winnipeg, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective271
- no adverse event209
- radioisotope scan abnormal158
- scan myocardial perfusion abnormal24
- nausea18
- headache16
- radiation overdose16
- rash15
- urticaria15
- pruritus14
- vomiting14
- product quality issue13
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2007 | 10 |
| 2008 | 30 |
| 2009 | 112 |
| 2010 | 87 |
| 2011 | 40 |
| 2012 | 7 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 10 |
| 2020 | 15 |
| 2021 | 30 |
| 2022 | 47 |
| 2023 | 25 |
| 2024 | 30 |
| 2025 | 73 |
| 2026 | 104 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Curium
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.